Recent Updates: REACH3, ROCKstar, and RWD

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

Now Viewing

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

EP: 10.AGAVE-201: Axatilimab for cGVHD

Video content above is prompted by the following:

1. Briefly discuss recent updates presented at ASH 2023 and TANDEM 2024:

• 3-year analysis of REACH3, ASH 2023
• 3-year follow-up of the ROCKstar study, TANDEM 2024

1. Brie fly discuss available real-world data (RWD) with ruxolitinib (Spałek A, et al. Pol Arch Intern Med. 2023) and ibrutinib (Chin KK, et al. Transplant Cell Ther. 2021;White J, et al. Transplant Cell Ther. 2023).